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Background: We examined the change in the use of rosiglitazone-containing products (RCPs) Canada-wide
between 2004 and 2010 and whether the rates of adverse events in association with RCP therapy in Canadian
patients changed in this period to better understand the real world use of RCP medications and as part of a
regulatory commitment by GlaxoSmithKline to Health Canada to assess whether there was an impact of a risk
communication on cardiac safety.
Methods: RCP utilization data were obtained from IMS Brogan’s longitudinal de-identified patient database (known
as LRx) that tracks prescription activity using store-based data collection from pharmacies in all Canadian provinces.
Adverse events (AEs), serious adverse events (SAEs) and cardiac AEs associated with RCP use in Canadian patients
between April 2004 and December 2010 were identified from GlaxoSmithKline’s AE database and, using the LRx
data, rates per 100,000 patients were estimated.
Results: A total of 239,184 patients were identified as having received at least one RCP prescription between 2004
and 2010 from the LRx. After excluding those with inconsistent gender or age, only one RCP prescription at the
pharmacy, a prescription from a pharmacy that had not consistently reported for the past six years or an
unreasonably high number of prescriptions, 180,936 patients remained for the analysis. The number of reports
identified from the AE database that occurred between April 2004 and December 2010 was 1,037. The average
monthly rates of AEs, SAEs and cardiac AEs decreased by 57%, 43% and 4%, respectively, between the observed
periods, April 2004-October 2007 and November 2007-December 2010.
Conclusions: The findings of this analysis demonstrate a significant decrease in RCP use in Canada following a
meta-analysis publication suggesting harm, which has been maintained. It is not possible to disentangle whether
the continuing decline can be attributed to the meta-analysis, the changes in prescribing guidelines, media
attention or a combination of some or all of these factors.
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Following the publication in May 2007 of a meta-
analysis [1] that suggested an increased risk of myocar-
dial infarction associated with rosiglitazone-containing
products (RCPs), a dramatic decrease in the use of RCPs
has been demonstrated in the United States and Europe
[2-5]. In Canada, two reports from Ontario and British
Columbia showed a similar decline in RCP use in those
provinces [6,7]. However, neither examined whether
there was an effect associated with a risk communication* Correspondence: Jorge.a.ross@gsk.com
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distribution, and reproduction in any mediumon cardiac safety issued by Health Canada in November
2007 [8], one component of which was that rosiglitazone
“is no longer approved as monotherapy for type 2 dia-
betes.” There was also a reminder that RCPs are not in-
dicated for use as a component of a triple therapy (i.e. in
combination with metformin and a sulfonylurea) dia-
betes regimen.
To better understand the real world use of RCP me-
dications and as part of a regulatory commitment by
GlaxoSmithKline (GSK) to Health Canada to assess
whether there was an impact of the risk communication
across Canada in terms of decreasing use of RCPs as
monotherapy or as part of triple or triple-plus therapy,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Figure 1 Number of patients receiving a rosiglitazone-containing product (RCP) by month, April 2004 to December 2010.
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wide between 2004 and 2010. The commitment also re-
quired an evaluation of the rates of adverse events (AEs),
especially cardiac AEs, in association with RCP therapy
in Canadian patients before and after the release of the
risk communication.
Methods
The only cross-Canada resource for drug utilization
commercially available is IMS Brogan’s longitudinal
de-identified patient database (known as LRx), which
tracks prescription activity using store-based data collec-
tion from pharmacies in all Canadian provinces [9]. LRx
covers 63% of prescriptions nationally and is recognized
as a critical national information source [10].
Patients dispensed prescriptions for RCPs, other oral
anti-diabetics or insulin between 2004 and 2010 were
identified from LRx and those dispensed RCPs alone or
in combination retained by IMS Brogan. Since LRx only
began in 2004 and data from the first three months are
misleading because they demonstrate the building of the
database rather than real utilization, the number of RCP
patients per month was calculated from April 2004 on-
wards. Since it is the usual way that IMS Brogan providesTable 1 Estimated average monthly rates of adverse events p
April 2004 - October 2007
Average Range 95
Adverse events 13.4 2.3-27.3 8.6
Serious adverse events 6.0 0.6-21.5 3.1
Cardiac adverse events 2.3 0.0-9.4 0.8data and because a national picture was required, propor-
tional allocation procedures established by IMS were used
to provide an estimate of overall national RCP use and as
monotherapy, in combination with another oral anti-
diabetic or insulin (dual therapy), or in combination with
multiple other anti-diabetic products (triple-plus therapy)
in the Canadian population of 34.5 million. These data
were provided to GSK.
AEs, serious adverse events (SAEs) and cardiac AEs
associated with RCP use in Canadian patients between
April 2004 and December 2010 were identified from
GSK’s AE database and, using the LRx data, rates per
100,000 patients were estimated. The AE database has
been approved by and information from it is shared with
regulatory agencies. It has been shown to be more com-
prehensive than both the US Food and Drug Adminis-
tration and the World Health Organization adverse
reaction databases for GSK’s products [11]. Nevertheless,
since the data come from voluntary reporting, they are
undoubtedly under-reported. In addition, the AE data
did not specify each patient’s RCP treatment regimen.
Since the data used in this analysis were de-identified,
ethics approval and patient consent were not required.
Moreover, because the analysis was focused on the impacter 100,000 patients in two time periods
November 2007 - December 2010
% CI Average Range 95% CI
-20.8 5.7 0.0-12.5 2.4-13.6
-11.5 3.4 0.0-8.7 1.1-10.6
-6.5 2.2 0.0-6.6 0.5-8.9
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prescribing requirements and cardiac AEs, information on
fractures or other AEs was not collected.
Results
A total of 239,184 patients were identified as having re-
ceived at least one RCP prescription between 2004 and
2010 from the LRx. After excluding those with inconsis-
tent gender or age (11,868), only one RCP prescription
at the pharmacy (9,669), a prescription from a pharmacy
that had not consistently reported for the past six years
(35,347), or an unreasonably high number of prescrip-
tions (1,364), 180,936 patients remained. These exclu-
sions remove a significant number of patients, but we
chose to be confident in the data that we used rather
than unsure about the reliability of part of the data.
The monthly number of RCP patients increased by
63% between April 2004 and the peak in May 2007. The
number subsequently decreased from the peak by 26% in
October 2007, 41% in February 2008, 58% in December
2009 and 70% in December 2010 (Figure 1). The monthly
numbers of mono, dual and triple-plus therapy patients
are also shown in Figure 1. Between May 2007 and De-
cember 2010, mono, dual and triple-plus therapy de-
creased by 80%, 70% and 65%, respectively.
The number of reports identified from GSK’s AE data-
base that occurred in Canadian patients between April
2004 and December 2010 was 1,037. Monthly rates of
AEs, SAEs and cardiac AEs (per 100,000 patients) were
estimated and the averages of these in two time periods
(April 2004 to October 2007 and November 2007 to
December 2010) calculated (Table 1). The average
monthly rates of AEs, SAEs and cardiac AEs decreased
by 57%, 43% and 4%, respectively, between the two
periods, but there were large overlapping confidence
intervals.
Discussion
The dispensing of RCPs across Canada decreased sub-
stantially from the peak in May 2007 to October 2007
and continued to decline after the November 2007 risk
communication [8] through to December 2010. These
results are consistent with other analyses in Canada [6,7]
and with studies in the United States and Europe [2-5].
However, due to the limited information available, it was
not possible to assess whether the risk communication
had any additional impact on an already decreasing
utilization pattern.
The largest decrease was in the monotherapy group
and the smallest in the triple-plus therapy group. The
former is consistent with the change in prescribing
guidelines [8]. The latter is not, but it should be recog-
nized that patients on triple-plus therapy are likely to be
further along the diabetes disease progression pathwayand to require multiple drugs to maintain glycemic con-
trol. In such patients, it may have been extremely diffi-
cult to find an effective product to replace the RCP.
Access to data on the use of other anti-diabetic drugs
may have provided greater insight into whether the risk
communication impacted therapy.
There was no evidence of an increased rate of adverse
events following the publication of the Health Canada
risk communication, which might have been anticipated
since patients potentially at risk may have been the ones
who discontinued RCP therapy. In fact, there was an ap-
parent decrease in the rate of all AEs and serious AEs.
The rate of cardiac AEs was already low so that a similar
decline was not likely to occur. Despite the comprehen-
siveness of the GSK AE database [11], the estimated
rates of adverse events are impacted by small numbers,
potentially due to under-reporting, and by the relatively
crude but best available method used to calculate them,
which is a significant limitation of this analysis. The lack
of information on each patient’s RCP treatment regimen
in the AE data was a further limitation.
Conclusions
The findings of this analysis demonstrate a major de-
crease in RCP use in Canada following the meta-analysis
publication, which has been maintained. It is not pos-
sible to disentangle whether the continuing decline can
be attributed to the meta-analysis, the changes in pres-
cribing guidelines, media attention or a combination of
some or all of these factors.
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